Intervet sees 6% global growth

Outpacing market growth, EBIT before incidentals increased 2% to EUR 213 million, resulting in an EBIT margin of 18.9%. Divestments and acquisitions had a negative impact on revenues of 3%.

In Europe, autonomous growth was 5%, while in North America, revenues from ongoing operations grew 12%. At the end of the year, Intervet received important product approvals for Zilmax®, a feed additive for cattle and PreveNile®, a West Nile Virus vaccine for horses.

Sign up for our
regular news updates

Latest Poultry Industry News

•   BIRD FLU: UK Bird Flu Restrictions Lifted
•   Barriers Need to be Broken to Help Farmers
•   New International Guidelines on Food Safety
•   Domesticated Storks Kill Flies in Vietnam
•   Hand in Hand: Alberta Industry and Research Centre
•   Remaining Restrictions Lifted in Oxfordshire
•   Aviagen Gets to Grips with Key Issues in Turkey
•   The Quest for a 'Green' Agricultural System
•   DEFRA: 21^st Century Challenges for Food Set in the UK
•   Egg Prices Thrive in Bangladesh Climate of Fear